Savoring Sabex: Sandoz' Play in Injectable Generics
Executive Summary
Sandoz, the generics unit of Novartis, is buying Sabex, a Canadian maker of injectable generics for $565 million cash, marking its entree into an attractive sector of generics and also the Canadian generics market. The 6X sales multiple aimed to dissuade Sabex owners from shopping for another buyer. Novartis is the only big pharma company to succeed in generics. Its play is opportunistic, but a secondary effect is a free-market response to pressure on big pharma to make drugs more affordable.
You may also be interested in...
Teva/Ivax: Generics' Answer to Big Pharma
Bigger generics companies aren't just the generic sector's problem. Giants such as the new Teva will present more formidable challenges to innovators, not just in patent wars but also with proprietary launches, and for a share of drug consumption in developing markets.
Teva/Ivax: Generics' Answer to Big Pharma
Bigger generics companies aren't just the generic sector's problem. Giants such as the new Teva will present more formidable challenges to innovators, not just in patent wars but also with proprietary launches, and for a share of drug consumption in developing markets.
Novartis/Hexal: Generic Consolidation, and More
Buying Hexal shows Novartis' commitment to generics. The Swiss group also hopes the move will bring more credibility, and better deals, across all of its businesses.